T H Jones

List of Publications by Year
in descending order

40 papers	5,818 citations	159585 30 h-index	289244 40 g-index
40 all docs	40 docs citations	40 times ranked	4334 citing authors

#	Article	IF	Citations
1	A new 2% testosterone gel formulation: a comparison with currently available topical preparations. Andrology, 2018, 6, 396-407.	3.5	17
2	Revascularization with percutaneous coronary intervention does not affect androgen status in males with chronic stable angina pectoris. Andrology, 2016, 4, 486-491.	3.5	2
3	The consensus recommendations of a group of international experts on the fundamental concepts related to the issues of testosterone deficiency and its treatment.. Obesity and Metabolism, 2016, 13, 15-31.	1.2	2
4	Testosterone and obesity. Obesity Reviews, 2015, 16, 581-606.	6.5	294
5	Testosterone deficiency and severity of erectile dysfunction are independently associated with reduced quality of life in men with type 2 diabetes. Andrology, 2014, 2, 205-211.	3.5	28
6	The role of androgen receptor CAG repeat polymorphism and other factors which affect the clinical response to testosterone replacement in metabolic syndrome and type 2 diabetes: TIMES2 sub-study. European Journal of Endocrinology, 2014, 170, 193-200.	3.7	19
7	Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology, 2014, 2, 819-834.	3.5	127
8	Dyslipidaemia is associated with testosterone, oestradiol and androgen receptor CAG repeat polymorphism in men with type 2 diabetes. Clinical Endocrinology, 2011, 74, 624-630.	2.4	37
9	Low Testosterone Associated With Obesity and the Metabolic Syndrome Contributes to Sexual Dysfunction and Cardiovascular Disease Risk in Men With Type 2 Diabetes. Diabetes Care, 2011, 34, 1669-1675.	8.6	286
10	Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the) Tj ETQq0 0 0 rgBT /Overlock 10	8.6	474
11	Low serum testosterone and increased mortality in men with coronary heart disease. Heart, 2010, 96, 1821-1825.	2.9	201
12	Testosterone deficiency: a risk factor for cardiovascular disease?. Trends in Endocrinology and Metabolism, 2010, 21, 496-503.	7.1	154
13	Statin Therapy Is Associated With Lower Total but Not Bioavailable or Free Testosterone in Men With Type 2 Diabetes. Diabetes Care, 2009, 32, 541-546.	8.6	69
14	Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. European Journal of Endocrinology, 2008, 159, 739-746.	3.7	74
15	Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes: Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care, 2007, 30, 911-917.	8.6	438
16	The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. European Journal of Endocrinology, 2007, 156, 595-602.	3.7	195
17	Testosterone replacement therapy. British Journal of Hospital Medicine (London, England: 2005), 2007, 68, 547-553.	0.5	6
18	Erectile dysfunction is associated with low bioactive testosterone levels and visceral adiposity in men with type 2 diabetes. Journal of Developmental and Physical Disabilities, 2007, 30, 500-507.	3.6	75

#	Article	IF	Citations
19	Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology, 2006, 154, 899-906.	3.7	669
20	Selective Inhibition of L-Type Ca2+ Channels in A7r5 Cells by Physiological Levels of Testosterone. Endocrinology, 2006, 147, 2675-2680.	2.8	99
21	Androgens, insulin resistance and vascular disease in men. Clinical Endocrinology, 2005, 63, 239-250.	2.4	256
22	Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina. European Journal of Endocrinology, 2005, 152, 285-291.	3.7	42
23	Smoking and hormones in health and endocrine disorders. European Journal of Endocrinology, 2005, 152, 491-499.	3.7	212
24	Testosterone replacement therapy: current trends and future directions. Human Reproduction Update, 2004, 10, 409-419.	10.8	191
25	Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart, 2004, 90, 871-876.	2.9	218
26	Testosterone treatment for men with chronic heart failure. British Heart Journal, 2004, 90, 446-447.	2.1	199
27	Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men. European Journal of Endocrinology, 2004, 150, 57-63.	3.7	26
28	Cardiovascular effects of testosterone: implications of the "male menopause"?. British Heart Journal, 2003, 89, 121-122.	2.1	38
29	Testosterone inhibits the prostaglandin F2alpha-mediated increase in intracellular calcium in A7r5 aortic smooth muscle cells: evidence of an antagonistic action upon store-operated calcium channels. Journal of Endocrinology, 2003, 178, 381-393.	2.6	17
30	Testosterone for secondary prevention in men with ischaemic heart disease?. QJM - Monthly Journal of the Association of Physicians, 2003, 96, 521-529.	0.5	44
31	Testosterone acts as a coronary vasodilator by a calcium antagonistic action. Journal of Endocrinological Investigation, 2002, 25, 455-458.	3.3	115
32	Gender Differences in the Vasomotor Effects of Different Steroid Hormones in Rat Pulmonary and Coronary Arteries. Hormone and Metabolic Research, 2001, 33, 645-652.	1.5	112
33	Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. European Heart Journal, 2000, 21, 890-894.	2.2	310
34	Testosterone: a natural tonic for the failing heart?. QJM - Monthly Journal of the Association of Physicians, 2000, 93, 689-694.	0.5	41
35	Low-Dose Transdermal Testosterone Therapy Improves Angina Threshold in Men With Chronic Stable Angina. Circulation, 2000, 102, 1906-1911.	1.6	560
36	Self-administered subcutaneous human menopausal gonadotrophin for the stimulation of testicular growth and the initiation of spermatogenesis in hypogonadotrophic hypogonadism. Clinical Endocrinology, 1993, 38, 203-208.	2.4	48

#	Article	IF	Citations
37	Effect of the GABA_A Agonist Muscimol on Prolactin Secretion from Human Prolactin-Secreting Adenomas and GH₃ Rat Pituitary Tumour Cells. Hormone Research, 1992, 37, 113-118.	1.8	4
38	INTERLEUKIN-6 SECRETING HUMAN PITUITARY ADENOMASIN VITRO. Journal of Clinical Endocrinology and Metabolism, 1991, 73, 207-209.	3.6	56
39	Bradykinin stimulates phosphoinositide metabolism and prolactin secretion in rat anterior pituitary cells. Journal of Molecular Endocrinology, 1989, 2, 47-53.	2.5	23
40	Evidence that angiotensin II is a paracrine agent mediating gonadotrophin-releasing hormone-stimulated inositol phosphate production and prolactin secretion in the rat. Journal of Endocrinology, 1988, 116, 367-371.	2.6	40